H. Lundbeck Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Charl van Zyl

Chief executive officer

DKK 39.6m

Total compensation

CEO salary percentage	6.8%
CEO tenure	1.2yrs
CEO ownership	n/a
Management average tenure	2.3yrs
Board average tenure	3.7yrs

Recent management updates

Recent updates

H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

Feb 22

H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

Feb 10

CEO Compensation Analysis

How has Charl van Zyl's remuneration changed compared to H. Lundbeck's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	DKK 3b
Jun 30 2024	n/a	n/a	DKK 3b
Mar 31 2024	n/a	n/a	DKK 2b
Dec 31 2023	DKK 40m	DKK 3m	DKK 2b

Compensation vs Market: Charl's total compensation ($USD5.59M) is above average for companies of similar size in the Danish market ($USD3.24M).

Compensation vs Earnings: Insufficient data to compare Charl's compensation with company performance.

CEO

Charl van Zyl (57 yo)

1.2yrs

Tenure

DKK 39,600,000

Compensation

Mr. Charl van Zyl served as Executive Vice President Neurology Solutions & Head of EU/International at UCB SA since February 2020 until June 2023. He serves as President and Chief Executive Officer of H. L...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Charl van Zyl	President & CEO	1.2yrs	DKK 39.60m	no data
Joerg Hornstein	CFO & Executive VP of Corporate Functions	2.3yrs	DKK 10.90m	0.0023% DKK 968.4k
Lars Bang	Executive Vice President of Product Development & Supply	5.8yrs	DKK 10.10m	0.038% DKK 16.3m
Per Luthman	Executive Vice President of Research & Development	5.8yrs	DKK 11.30m	0.014% DKK 6.0m
Tarek Samad	Senior VP & Head of Research	3.5yrs	no data	no data
Palle Olesen	Chief Specialist & VP of Investor Relations	no data	no data	no data
Tine Hansen	Senior Vice President of Corporate Communications & Public Affairs	less than a year	no data	no data
Dianne Holto	Executive Vice President of People & Culture	less than a year	no data	no data
Ole Chrintz	Senior Vice President of International Markets	no data	no data	no data
Rupert Sandbrink	Senior VP & Head of Clinical Development	2.8yrs	no data	no data
Bjorn Mogensen	Senior Vice President of Group Finance	2.3yrs	no data	no data
Jose Molinuevo	VP & Head of Experimental Medicine	no data	no data	no data

2.3yrs

Average Tenure

58.5yo

Average Age

Experienced Management: HLUN B's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Lars Rasmussen	Independent Chairman	11.8yrs	DKK 1.70m	0.010% DKK 4.3m
Lene Skole-Sorensen	Deputy Chairman	9.8yrs	DKK 1.20m	0.0062% DKK 2.6m
Jeffrey Berkowitz	Independent Director	6.7yrs	DKK 1.20m	no data
Lars Holmqvist	Director	9.8yrs	DKK 600.00k	0.0076% DKK 3.2m
Jakob Riis	Director	1.7yrs	DKK 450.00k	0.0055% DKK 2.3m
Ilse Wenzel	Independent Director	3.7yrs	DKK 70.00k	no data
Santiago Arroyo	Independent Director	3.7yrs	DKK 1.00m	no data
Camilla Andersson	Employee Representative Director	2.7yrs	DKK 400.00k	0.00010% DKK 42.7k
Dorte Clausen	Employee Representative Director	2.7yrs	DKK 400.00k	0.00011% DKK 46.9k
Hossein Armandi	Employee Representative Director	2.7yrs	DKK 400.00k	no data
Lasse Skibsbye	Employee Representative Director	2.7yrs	DKK 400.00k	no data

3.7yrs

Average Tenure

58yo

Average Age

Experienced Board: HLUN B's board of directors are considered experienced (3.7 years average tenure).

H. Lundbeck Management

Management criteria checks 2/4

Key information

Recent management updates

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

H. Lundbeck A/S Announces Management Appointments

Key Executive recently bought kr.751k worth of stock

Less than half of directors are independent

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck (CPH:HLUN B) Seems To Use Debt Quite Sensibly

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease

Investors Aren't Entirely Convinced By H. Lundbeck A/S' (CPH:HLUN B) Earnings

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Price target increased by 9.4% to kr.45.54

Do H. Lundbeck's (CPH:HLUN B) Earnings Warrant Your Attention?

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Investors Interested In H. Lundbeck A/S' (CPH:HLUN B) Earnings

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

Upcoming dividend of kr.0.70 per share

H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.70

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

Key Executive recently bought kr.751k worth of stock

H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

Less than half of directors are independent

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age